Cargando…

Mesenchymal Stem Cells Prevent the Rejection of Fully Allogenic Islet Grafts by the Immunosuppressive Activity of Matrix Metalloproteinase-2 and -9

OBJECTIVE: Mesenchymal stem cells (MSCs) are known to be capable of suppressing immune responses, but the molecular mechanisms involved and the therapeutic potential of MSCs remain to be clarified. RESEARCH DESIGN AND METHODS: We investigated the molecular mechanisms underlying the immunosuppressive...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Yunchuan, Xu, Danmei, Feng, Gang, Bushell, Andrew, Muschel, Ruth J., Wood, Kathryn J.
Formato: Texto
Lenguaje:English
Publicado: American Diabetes Association 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2712800/
https://www.ncbi.nlm.nih.gov/pubmed/19509016
http://dx.doi.org/10.2337/db09-0317
_version_ 1782169536128090112
author Ding, Yunchuan
Xu, Danmei
Feng, Gang
Bushell, Andrew
Muschel, Ruth J.
Wood, Kathryn J.
author_facet Ding, Yunchuan
Xu, Danmei
Feng, Gang
Bushell, Andrew
Muschel, Ruth J.
Wood, Kathryn J.
author_sort Ding, Yunchuan
collection PubMed
description OBJECTIVE: Mesenchymal stem cells (MSCs) are known to be capable of suppressing immune responses, but the molecular mechanisms involved and the therapeutic potential of MSCs remain to be clarified. RESEARCH DESIGN AND METHODS: We investigated the molecular mechanisms underlying the immunosuppressive effects of MSCs in vitro and in vivo. RESULTS: Our results demonstrate that matrix metalloproteinases (MMPs) secreted by MSCs, in particular MMP-2 and MMP-9, play an important role in the suppressive activity of MSCs by reducing surface expression of CD25 on responding T-cells. Blocking the activity of MMP-2 and MMP-9 in vitro completely abolished the suppression of T-cell proliferation by MSCs and restored T-cell expression of CD25 as well as responsiveness to interleukin-2. In vivo, administration of MSCs significantly reduced delayed-type hypersensitivity responses to allogeneic antigen and profoundly prolonged the survival of fully allogeneic islet grafts in transplant recipients. Significantly, these MSC-mediated protective effects were completely reversed by in vivo inhibition of MMP-2 and MMP-9. CONCLUSIONS: We demonstrate that MSCs can prevent islet allograft rejection leading to stable, long-term normoglycemia. In addition, we provide a novel insight into the mechanism underlying the suppressive effects of MSCs on T-cell responses to alloantigen.
format Text
id pubmed-2712800
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-27128002010-08-01 Mesenchymal Stem Cells Prevent the Rejection of Fully Allogenic Islet Grafts by the Immunosuppressive Activity of Matrix Metalloproteinase-2 and -9 Ding, Yunchuan Xu, Danmei Feng, Gang Bushell, Andrew Muschel, Ruth J. Wood, Kathryn J. Diabetes Original Article OBJECTIVE: Mesenchymal stem cells (MSCs) are known to be capable of suppressing immune responses, but the molecular mechanisms involved and the therapeutic potential of MSCs remain to be clarified. RESEARCH DESIGN AND METHODS: We investigated the molecular mechanisms underlying the immunosuppressive effects of MSCs in vitro and in vivo. RESULTS: Our results demonstrate that matrix metalloproteinases (MMPs) secreted by MSCs, in particular MMP-2 and MMP-9, play an important role in the suppressive activity of MSCs by reducing surface expression of CD25 on responding T-cells. Blocking the activity of MMP-2 and MMP-9 in vitro completely abolished the suppression of T-cell proliferation by MSCs and restored T-cell expression of CD25 as well as responsiveness to interleukin-2. In vivo, administration of MSCs significantly reduced delayed-type hypersensitivity responses to allogeneic antigen and profoundly prolonged the survival of fully allogeneic islet grafts in transplant recipients. Significantly, these MSC-mediated protective effects were completely reversed by in vivo inhibition of MMP-2 and MMP-9. CONCLUSIONS: We demonstrate that MSCs can prevent islet allograft rejection leading to stable, long-term normoglycemia. In addition, we provide a novel insight into the mechanism underlying the suppressive effects of MSCs on T-cell responses to alloantigen. American Diabetes Association 2009-08 2009-06-09 /pmc/articles/PMC2712800/ /pubmed/19509016 http://dx.doi.org/10.2337/db09-0317 Text en © 2009 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
spellingShingle Original Article
Ding, Yunchuan
Xu, Danmei
Feng, Gang
Bushell, Andrew
Muschel, Ruth J.
Wood, Kathryn J.
Mesenchymal Stem Cells Prevent the Rejection of Fully Allogenic Islet Grafts by the Immunosuppressive Activity of Matrix Metalloproteinase-2 and -9
title Mesenchymal Stem Cells Prevent the Rejection of Fully Allogenic Islet Grafts by the Immunosuppressive Activity of Matrix Metalloproteinase-2 and -9
title_full Mesenchymal Stem Cells Prevent the Rejection of Fully Allogenic Islet Grafts by the Immunosuppressive Activity of Matrix Metalloproteinase-2 and -9
title_fullStr Mesenchymal Stem Cells Prevent the Rejection of Fully Allogenic Islet Grafts by the Immunosuppressive Activity of Matrix Metalloproteinase-2 and -9
title_full_unstemmed Mesenchymal Stem Cells Prevent the Rejection of Fully Allogenic Islet Grafts by the Immunosuppressive Activity of Matrix Metalloproteinase-2 and -9
title_short Mesenchymal Stem Cells Prevent the Rejection of Fully Allogenic Islet Grafts by the Immunosuppressive Activity of Matrix Metalloproteinase-2 and -9
title_sort mesenchymal stem cells prevent the rejection of fully allogenic islet grafts by the immunosuppressive activity of matrix metalloproteinase-2 and -9
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2712800/
https://www.ncbi.nlm.nih.gov/pubmed/19509016
http://dx.doi.org/10.2337/db09-0317
work_keys_str_mv AT dingyunchuan mesenchymalstemcellspreventtherejectionoffullyallogenicisletgraftsbytheimmunosuppressiveactivityofmatrixmetalloproteinase2and9
AT xudanmei mesenchymalstemcellspreventtherejectionoffullyallogenicisletgraftsbytheimmunosuppressiveactivityofmatrixmetalloproteinase2and9
AT fenggang mesenchymalstemcellspreventtherejectionoffullyallogenicisletgraftsbytheimmunosuppressiveactivityofmatrixmetalloproteinase2and9
AT bushellandrew mesenchymalstemcellspreventtherejectionoffullyallogenicisletgraftsbytheimmunosuppressiveactivityofmatrixmetalloproteinase2and9
AT muschelruthj mesenchymalstemcellspreventtherejectionoffullyallogenicisletgraftsbytheimmunosuppressiveactivityofmatrixmetalloproteinase2and9
AT woodkathrynj mesenchymalstemcellspreventtherejectionoffullyallogenicisletgraftsbytheimmunosuppressiveactivityofmatrixmetalloproteinase2and9